Figure 3.
Bcl-xLexpression suppresses activation of mitochondrial phospholipase A2. Increasing concentrations (0.1-100 μM as indicated) of arachidonic acid induce phospholipase A2 activation and enhance anti-IgM–(1 μg/mL) stimulated PLA2 activation (A) as determined by the increased release (intracellular and extracellular) of [3H]arachidonic acid from cellular [3H]arachidonic acid–labeled phosphatidylcholine as described in “Materials and methods.” Due to the loss of [3H]arachidonic acid during the cellular fractionation process, anti-IgM–(1 μg/mL) stimulated mitochondrial phospholipase A2 activation (B-C) was therefore determined by the measurement of decreased levels of [3H]arachidonic acid–labeled phosphatidylcholine in isolated mitochondria derived from wild-type (B) and Bcl-xL (C) overexpressing WEHI-231 B cells. Data are representative of at least 3 independent experiments. (D) WEHI-231 B cells were cultured for 48 hours with medium or anti-IgM (10 μg/mL) in the presence and absence of oligomycin (OM, 8 ng/mL) or cyclosporin A (CSA, 1 nM), and percent of apoptotic cells was measured by PI staining of subdiploid DNA content as described in “Materials and methods.” (E) WEHI-231 B cells were cultured for 3 hours with medium or anti-IgM (10 μg/mL) in the presence and absence of oligomycin (OM, 8 ng/mL) or cyclosporin A (CSA, 1 nM), and isolated mitochondria were prepared. PLA2 activity was assayed using the PLA2 assay kit as described in “Materials and methods.” Data are presented as means ± SD in which n = 3 and from single experiments that are representative of at least 3 independent experiments.